Go Pro
NYSE:INFU

InfuSystem (INFU) Stock Price, News & Analysis

InfuSystem logo
$12.87 +0.16 (+1.26%)
Closing price 04:00 PM Eastern
Extended Trading
$12.79 -0.08 (-0.62%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About InfuSystem Stock (NYSE:INFU)

Advanced

Key Stats

Today's Range
$12.59
▼
$12.89
50-Day Range
$8.89
▼
$13.11
52-Week Range
$7.29
▼
$13.20
Volume
108,387 shs
Average Volume
163,644 shs
Market Capitalization
$259.74 million
P/E Ratio
214.54
Dividend Yield
N/A
Price Target
$17.50
Consensus Rating
Moderate Buy

Company Overview

InfuSystem Holdings, Inc. is a healthcare services company that provides ambulatory infusion pump management and related services. The company supports patients, healthcare providers, manufacturers and payors by supplying infusion pumps, equipment, disposable supplies and clinical support for therapies administered outside traditional hospital settings.

Its services include the rental, sale, maintenance and repair of infusion pumps, as well as equipment logistics, billing support and patient assistance. InfuSystem also provides biomedical and equipment-management services to healthcare organizations and manufacturers. Its solutions are used in areas such as oncology, pain management, immunoglobulin therapy, antibiotics and other home and ambulatory infusion treatments.

Founded in 2005 and headquartered in Rochester Hills, Michigan, InfuSystem serves customers across the United States and Canada. The company operates through service offerings focused on patient care and integrated therapy support, helping coordinate the equipment and services required for infusion treatment in home, clinic and other outpatient environments.

AI Generated. May Contain Errors.

InfuSystem Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

INFU MarketRank™: 

InfuSystem scored higher than 77% of companies evaluated by MarketBeat, and ranked 142nd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    InfuSystem has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    InfuSystem has a consensus price target of $17.50, representing about 36.0% upside from its current price of $12.87.

  • Amount of Analyst Coverage

    InfuSystem has only been the subject of 1 research reports in the past 90 days.

  • Read more about InfuSystem's stock forecast and price target.
  • Earnings Growth

    Earnings for InfuSystem are expected to grow by 106.67% in the coming year, from $0.15 to $0.31 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InfuSystem is 214.54, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 42.18.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InfuSystem is 214.54, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 214.73.

  • Price to Book Value per Share Ratio

    InfuSystem has a P/B Ratio of 5.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for INFU.
  • Dividend Yield

    InfuSystem does not currently pay a dividend.

  • Dividend Growth

    InfuSystem does not have a long track record of dividend growth.

  • News Sentiment

    InfuSystem has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for InfuSystem this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for INFU on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added InfuSystem to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, InfuSystem insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.80% of the stock of InfuSystem is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.13% of the stock of InfuSystem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about InfuSystem's insider trading history.
Receive INFU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InfuSystem and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INFU Stock News Headlines

Transcript : InfuSystem Holdings, Inc. - Special Call
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing December 8th.tc pixel
Comparing InfuSystem (NYSE:INFU) & UnitedHealth Group (NYSE:UNH)
InfuSystem Holdings Inc
Contrasting Guardant Health (NASDAQ:GH) & InfuSystem (NYSE:INFU)
InfuSystem (NYSE:INFU) vs. Exagen (NASDAQ:XGN) Head to Head Comparison
InfuSystem to Host Investor Webcast on September 24, 2026
See More Headlines

INFU Stock Analysis - Frequently Asked Questions

InfuSystem's stock was trading at $8.97 at the beginning of 2026. Since then, INFU stock has increased by 43.5% and is now trading at $12.87.

InfuSystem Holdings, Inc. (NYSE:INFU) released its earnings results on Thursday, November, 7th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.08. The business earned $35.32 million during the quarter, compared to the consensus estimate of $35.50 million. InfuSystem had a net margin of 1.12% and a trailing twelve-month return on equity of 2.78%.

InfuSystem's Board of Directors authorized a stock buyback program on Tuesday, May 19th 2026, which permits the company to buy back $20,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 10.3% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board believes its stock is undervalued.

InfuSystem's top institutional shareholders include BlackRock Inc. (7.86%), Punch & Associates Investment Management Inc. (4.14%), Heartland Advisors Inc. (3.47%) and Diamond Hill Capital Management LLC Investment Advisor (2.42%). Insiders that own company stock include Richard Dilorio, Carrie Lachance, Barry G Steele, Scott Shuda, Paul Andrew Gendron, Addam Chupa, Ralph F Boyd Jr and Kenneth D Eichenbaum.
View institutional ownership trends
.

Shares of INFU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that InfuSystem investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Home Depot (HD), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
11/07/2024
Today
9/28/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NYSE:INFU
Previous Symbol
NYSE:INFU
CIK
1337013
Employees
473
Year Founded
2005

Price Target and Rating

High Price Target
$20.00
Low Price Target
$15.00
Potential Upside/Downside
+36.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.41
Trailing P/E Ratio
214.54
Forward P/E Ratio
85.80
P/E Growth
N/A
Net Income
$870 thousand
Net Margins
1.12%
Pretax Margin
2.65%
Return on Equity
2.78%
Return on Assets
1.41%

Debt

Debt-to-Equity Ratio
0.50
Current Ratio
1.98
Quick Ratio
1.59

Sales & Book Value

Annual Sales
$143.34 million
Price / Sales
1.81
Cash Flow
$1.01 per share
Price / Cash Flow
12.79
Book Value
$2.47 per share
Price / Book
5.21

Miscellaneous

Outstanding Shares
20,182,000
Free Float
19,095,000
Market Cap
$259.74 million
Optionable
Optionable
Beta
1.50

Social Links

10 Best Stocks to Own: Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NYSE:INFU) was last updated on 9/28/2026 by MarketBeat.com Staff.
From Our Partners